Biocept to Release Second Quarter 2020 Financial Results and Host Investor Conference Call on August 12, 2020

Rhea-AI Summary

Biocept, Inc. (NASDAQ: BIOC) will release its financial results for the second quarter of 2020 on August 12, 2020, after market close. The company has scheduled a conference call at 4:30 p.m. Eastern time to discuss these results and address questions from the investment community. Biocept specializes in liquid biopsy tests that help physicians obtain critical information for improving cancer treatment outcomes. Their proprietary Target Selector™ technology enables the capture and analysis of tumor-associated molecular markers.

Positive

• Scheduled release of financial results may indicate transparency and investor engagement.
• Continued focus on innovative liquid biopsy technology to enhance cancer diagnosis and treatment.

Negative

• None.

SAN DIEGO, Aug. 4, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it will release financial results for the three and six months ended June 30, 2020 after the market closes on Wednesday, August 12, 2020.  The Company will host a conference call for the investment community to discuss the results and answer questions at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).

Individuals interested in participating on the conference call may do so by dialing (855) 656-0927 for domestic callers, (855) 669-9657 for Canadian callers, or (412) 902-4109 for other international callers.  Those interested in listening to a webcast of the live conference call may do so by visiting https://www.webcaster4.com/Webcast/Page/1271/35627.

A replay of the conference call will be available for 48 hours following the conclusion of the call by dialing (877) 344-7529 for domestic callers, (855) 669-9658 for Canadian callers, or (412) 317-0088 for other international callers, and entering the replay access code 10145918.  A webcast replay will be available for 90 days at http://ir.biocept.com/events.cfm.

About Biocept

Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma.  The Company uses its proprietary liquid biopsy technology to provide physicians with information for treating and monitoring patients diagnosed with cancer. The Company's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in plasma (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. For additional information, please visit www.biocept.com.

Contact:              
LHA Investor Relations
Jody Cain
Jcain@lhai.com
310-691-7100

View original content to download multimedia:http://www.prnewswire.com/news-releases/biocept-to-release-second-quarter-2020-financial-results-and-host-investor-conference-call-on-august-12-2020-301104404.html

SOURCE Biocept, Inc.

FAQ

When will Biocept release its financial results for Q2 2020?

Biocept will release its Q2 2020 financial results on August 12, 2020.

What time is the Biocept conference call?

The conference call will take place at 4:30 p.m. Eastern time.

How can I listen to the Biocept conference call?

Participants can listen to the conference call by dialing (855) 656-0927 for domestic callers or via the webcast available on their website.

What technology does Biocept use for cancer testing?

Biocept uses its proprietary Target Selector™ liquid biopsy technology to analyze tumor-associated molecular markers.